



## Ensuring Diversity in a COVID-19 Study.

**Accelerating access to patients in underserved communities and a diverse population**

### Situation

Enabling **rapid response** to a public health crisis

The non-profit sponsor, conducting a study evaluating the safety and efficacy of a prescription blood thinner, aimed to more quickly realize if the intervention was effective for high-risk patients with mild COVID-19. Science 37 offered a flexible approach to quickly access a more representative patient population.

### Solution

Decentralization for a more **representative patient population**

Utilizing the Science 37 Operating System™, underpinned by our end-to-end technology platform and specialized networks, we were able to tap into our Global Healthcare Provider Network to identify sites that could enroll patients via high-recruiting providers utilizing targeted, digital outreach strategies, telemedicine, and direct-to-patient study supplies.

### Impact

Greater **diversity and pivoting** the study

By leveraging our Operating System and activating our virtual study arm (known as Metasite™) to supplement a network of traditional sites, the sponsor was able to access high-risk patients, typically underserved by clinical trials, without geographic boundaries, and more quickly realize the intervention's ineffectiveness and re-prioritize efforts on more viable treatment options.

- Facilitating enrollment of 90% of the target population in five months
- Enabling a more representative patient population of 27% non-white patients by the end of the trial

*“What was really a good learning is that every specific population needs representation in clinical trials. And I think that’s a field that will evolve significantly after COVID.”*

**– Sponsor**

## Our bespoke approach to every trial

We take a bespoke approach to all our trials. We understand every therapeutic area is different and perform careful review of trial design, inclusion/exclusion criteria, and review of the specific needs and/or study participation challenges expressed from diverse patients and providers to do our part to reduce barriers and support clinical trial equity.

## Let's Talk.

Please contact us at [diversityinnovation@science37.com](mailto:diversityinnovation@science37.com) to learn more about how we do Diversity in Clinical Trials.

---

## About Science 37

Science 37 accelerates clinical research by enabling universal access to patients and providers, anywhere. The Science 37 Operating System™—underpinned by an end-to-end technology platform and supported by specialized networks to enable trial orchestration—enables up to 15x faster trial enrollment, 28% greater patient retention and 3x more diversity. Science 37 and its Operating System can be configured to conduct the full clinical trial, act as a virtual site (known as Metasite™) or deploy its technology in combination with any of its specialized networks to enable flexibility across nearly any study design. Founded in 2014 as a pioneer in decentralized clinical trials, Science 37 has conducted more fully decentralized, interventional clinical trials than any other provider and has the most complete Operating System.

---

### CONTACT US

[diversityinnovation@science37.com](mailto:diversityinnovation@science37.com)  
[science37.com](https://science37.com)

